<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03714815</url>
  </required_header>
  <id_info>
    <org_study_id>AC-055G203</org_study_id>
    <secondary_id>2018-001603-37</secondary_id>
    <nct_id>NCT03714815</nct_id>
  </id_info>
  <brief_title>A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease</brief_title>
  <acronym>SERENADE OL</acronym>
  <official_title>A Long-term, Multicenter, Single-arm, Open-label Extension of the SERENADE Study, to Assess the Safety and Efficacy of Macitentan in Subjects With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Almac Clinical Technologies, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Frontier Science &amp; Technology Research Foundation, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Covance Central Laboratory Services, LP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiltern International Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>WorldCare Clinical, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AcitGraph</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medidata Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this open-label (OL) extension trial is to study the long-term safety and efficacy
      of macitentan in subjects with heart failure with preserved ejection fraction (HFpEF) and
      pulmonary vascular disease (PVD) beyond the treatment in the double-blind parent SERENADE
      study (AC-055G202, NCT03153111). Furthermore, this OL extension study will give eligible
      subjects of the main study (SERENADE/AC-055G202, NCT03153111) an opportunity to continue or
      start receiving macitentan.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 7, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">May 4, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Subjects who remained in main study (SERENADE/AC-055G202, NCT03153111) after randomization and who meet the eligibility criteria described will be eligible to enter this single-arm OL extension study. All enrolled subjects will receive macitentan 10 mg. For this OL extension study no primary efficacy endpoint has been defined and all efficacy endpoints are of exploratory nature. The ones listed below are considered safety endpoints.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of All-cause Deaths Occurring up to 30 days After Study Treatment Discontinuation (End of Study Visit [EOS])</measure>
    <time_frame>Up to 30 days after study treatment discontinuation (up to end of study visit [Week 438])</time_frame>
    <description>Number of all-cause deaths occurring up to 30 days after study treatment discontinuation will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of All-cause Hospital Admissions up to 30 days after Study Treatment Discontinuation (EOS)</measure>
    <time_frame>Up to 30 days after study treatment discontinuation (up to end of study visit [Week 438])</time_frame>
    <description>Number of all-cause hospital admissions up to 30 days after study treatment discontinuation will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Treatment-Emergent Adverse Events (AE's) After Study Treatment Discontinuation</measure>
    <time_frame>Up to 30 days after study treatment discontinuation (up to end of study visit [Week 438])</time_frame>
    <description>A treatment-emergent AE is any AE temporally associated with the use of study treatment, whether or not it is considered by the investigator as related to study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Treatment-Emergent Serious Adverse Events (SAE's) After Study Treatment Discontinuation</measure>
    <time_frame>Up to 30 days after study treatment discontinuation (up to end of study visit [Week 438])</time_frame>
    <description>A treatment-emergent SAEs is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) Leading to Premature Discontinuation of study Treatment</measure>
    <time_frame>Up to end of study visit (Week 438)</time_frame>
    <description>Number of participants with AEs leading to premature discontinuation of study treatment up to end of study visit will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Systolic Arterial Blood Pressure</measure>
    <time_frame>Baseline to end of study visit (Week 438)</time_frame>
    <description>Change from baseline in systolic arterial blood pressure as assessed by electrocardiogram (ECG) will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Diastolic Arterial Blood Pressure</measure>
    <time_frame>Baseline to end of study visit (Week 438)</time_frame>
    <description>Change from baseline in diastolic arterial pressure as assessed by ECG will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Pulse Rate</measure>
    <time_frame>Baseline to end of study visit (Week 438)</time_frame>
    <description>Change from baseline in pulse rate as assessed by ECG will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Body Weight</measure>
    <time_frame>Baseline to end of study visit (Week 438)</time_frame>
    <description>Change from baseline in body weight will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Abnormalities in Clinical Laboratory Parameters up to 30 days after study Treatment Discontinuation</measure>
    <time_frame>Up to 30 days after study treatment discontinuation (up to end of study visit [Week 438])</time_frame>
    <description>Percentage of participants with abnormalities in clinical laboratory parameters up to 30 days after study treatment discontinuation will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Laboratory Parameter (Hemoglobin)</measure>
    <time_frame>Baseline to end of study visit (Week 438)</time_frame>
    <description>Change from baseline in laboratory parameter hemoglobin will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Laboratory Parameter (Hematocrit)</measure>
    <time_frame>Baseline to end of study visit (Week 438)</time_frame>
    <description>Change from baseline in laboratory parameter hematocrit will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Laboratory Parameter (Erythrocyte Count)</measure>
    <time_frame>Baseline to end of study visit (Week 438)</time_frame>
    <description>Change from baseline in laboratory parameter erythrocyte count will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Laboratory Parameters (Leukocyte Count and Platelet Count)</measure>
    <time_frame>Baseline to end of study visit (Week 438)</time_frame>
    <description>Change from baseline in laboratory parameters leukocyte count and platelet count will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Laboratory Parameters (Alanine Aminotransferase [ALT], Alkaline Phosphatase and Aspartate Aminotransferase [AST])</measure>
    <time_frame>Baseline to end of study visit (Week 438)</time_frame>
    <description>Change from baseline in laboratory parameters ALT, alkaline phosphatase and AST will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Laboratory Parameters (Total and Direct Bilirubin, Creatinine, Blood Urea Nitrogen, Uric acid)</measure>
    <time_frame>Baseline to end of study visit (Week 438)</time_frame>
    <description>Change from baseline in laboratory parameters total and direct bilirubin, creatinine, blood urea nitrogen, uric acid will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Laboratory Parameters (Sodium, Potassium, Chloride, Calcium, Magnesium)</measure>
    <time_frame>Baseline to end of study visit (Week 438)</time_frame>
    <description>Change from baseline in laboratory parameters sodium, potassium, chloride, calcium, magnesium will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Laboratory Parameters (Total Protein and Albumin)</measure>
    <time_frame>Baseline to end of study visit (Week 438)</time_frame>
    <description>Change from baseline in laboratory parameters total protein and albumin will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Laboratory Parameter (Albumin / Globulins Ratio)</measure>
    <time_frame>Baseline to end of study visit (Week 438)</time_frame>
    <description>Change from baseline in laboratory parameter albumin/globulins ratio will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Laboratory Parameter (N-Terminal pro-Brain Natriuretic Peptide [NT-proBNP])</measure>
    <time_frame>Baseline to end of study visit (Week 438)</time_frame>
    <description>Change from baseline in laboratory parameter NT-proBNP will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Laboratory Parameters (Mid-Regional pro-Atrial Natriuretic Peptide [MR-proANP])</measure>
    <time_frame>Baseline to end of study visit (Week 438)</time_frame>
    <description>Change from baseline in laboratory parameters MR-proANP will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>Baseline to end of study visit (Week 438)</time_frame>
    <description>Change from baseline in eGFR will be reported.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease</condition>
  <arm_group>
    <arm_group_label>Open-label treatment period</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration of 10 mg macitentan once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>macitentan 10 mg</intervention_name>
    <description>macitentan 10 mg, film-coated tablet, oral use</description>
    <arm_group_label>Open-label treatment period</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated Informed Consent Form (ICF).

          2. Subject remained in the main study (SERENADE/AC-055G202, NCT03153111) for: a) 52 weeks
             after randomization if entered this Open-label (OL) extension study prior to protocol
             Version 4, b) At least 24 weeks after randomization if entering this OL extension
             study under protocol Version 4

          3. A woman of childbearing potential is eligible only if all of the following apply:

               -  Negative pre-treatment serum pregnancy test.

               -  Agreement to undertake monthly pregnancy tests from the enrollment visit up to at
                  least 30 days after study treatment discontinuation.

               -  Agreement to use reliable contraception from at least 30 days prior to the
                  enrollment visit up to at least 30 days after study treatment discontinuation.

        Exclusion Criteria:

          1. Premature discontinuation of study treatment in the main study (SERENADE/AC-055G202,
             NCT03153111) due to an adverse event related to:

               1. Edema or fluid retention

               2. Worsening of heart failure

               3. Liver aminotransferase elevation

               4. Study treatment, based on investigators' discretion

          2. Liver aminotransferase elevations, at the enrollment visit, fulfilling the following
             criteria:

               1. Alanine amino transferase (ALT) / aspartate aminotransferase (AST) ≥ 8 × the
                  upper limit of normal (ULN)

               2. ALT/AST ≥ 3 × ULN and associated clinical symptoms of liver injury, e.g., nausea,
                  vomiting, fever, abdominal pain, jaundice, unusual lethargy or fatigue, flu-like
                  syndrome (arthralgia, myalgia, fever)

               3. ALT/AST ≥ 3 × ULN and associated increase in total bilirubin to ≥ 2 × ULN

          3. Treatment with the following forbidden medications within 1 month prior to the
             enrollment visit:

               1. Treatments that may interfere with the assessment of efficacy (i.e., endothelin
                  receptor antagonists, prostanoids, phosphodiesterase-5 inhibitors, guanylate
                  cyclase stimulators)

               2. Strong cytochrome P-450 3A4 (CYP3A4) inducers such as rifabutin, rifampin,
                  rifampicin, rifapentin, carbamazepine, phenobarbital, phenytoin, or St. John's
                  wort

               3. Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, voriconazole,
                  clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir.

               4. any other investigational treatment

          4. Pregnant, planning to be become pregnant or lactating.

          5. Any known factor or disease that might interfere with treatment compliance, study
             conduct, or interpretation of the results, such as drug or alcohol dependence or
             psychiatric disease.

          6. Known hypersensitivity to macitentan or drugs of the same class, or any of the study
             drug excipients (e.g., soy lecithin, lactose)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly Papadakis, MD</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South Denver Cardiology Associates PC</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Iowa - Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Clinical Trial Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219-2906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Dallas Research Associates</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Heart and Vascular Institute</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Saint Lukes Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas Mar del Plata</name>
      <address>
        <city>Mar del Plata</city>
        <zip>B7600FZN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maestri E Kormann Consultoria Médico- Científica Ltda</name>
      <address>
        <city>Blumenau</city>
        <zip>89020-430</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto do Coração de Marília</name>
      <address>
        <city>Marilia</city>
        <zip>17515-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic - Consulting Center I-Sliven</name>
      <address>
        <city>Sliven</city>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre Synexus</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Og Frederiksberg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hôpital Albert Michallon</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Bicetre</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rouen - Hopital Charles Nicolle</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Medizinische Klinik und Poliklinik 1-Pneumologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Giessen</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Uniklinik Köln Klinik III für Innere Medizin</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Városmajor Szív- és Érgyógyászati Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>3810101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3339419</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galilee Medical Center</name>
      <address>
        <city>Nahariya</city>
        <zip>2210001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson Campus</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>7610001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalityczny im. Jana Pawla II, Oddzial Kliniczny Chorob Serca i Naczyn</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. Stefana Kardynala Wyszynskiego SPZOZ</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4 Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-981</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiomed</name>
      <address>
        <city>Craiova</city>
        <zip>200505</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SAL MED Pitesti</name>
      <address>
        <city>Pitesti</city>
        <zip>110437</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cmi Dr Podoleanu Cristian</name>
      <address>
        <city>Targu-Mures</city>
        <zip>540503</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ekaterinburg City Clinical Hospital #14</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Scientific Institution</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Clinical Hospital No.51</name>
      <address>
        <city>Moscow</city>
        <zip>121309</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical Research Center of Cardiology of MoH of Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution</name>
      <address>
        <city>St Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetsjukhuset</name>
      <address>
        <city>Goteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2RX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czechia</country>
  </removed_countries>
  <link>
    <url>http://pam.sylogent.com/cr/AC-055G203</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary vascular disease</keyword>
  <keyword>macitentan</keyword>
  <keyword>heart failure with preserved ejection fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macitentan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials\transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

